---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-21-000141"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:13:43.667597+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte completes €260M acquisition of HalioDx in cash and stock

## Summary
- Total consideration €260M: ~€147M cash + ~€113M in Veracyte common stock.
- Acquisition of HalioDx, a French immuno-oncology diagnostics company.
- Closing on August 2, 2021, as previously announced June 1 and July 13.
- Stock consideration issued as unregistered securities under Item 3.02.

## SEC filing metadata
- accession: 0001384101-21-000141
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410121000141/0001384101-21-000141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410121000141/vcyt-20210802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-21-000141
- JSON: https://secwatch.observer/filing/0001384101-21-000141.json
- Plain text: https://secwatch.observer/filing/0001384101-21-000141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.